Compare SCHL & TBPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SCHL | TBPH |
|---|---|---|
| Founded | 1920 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Books | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 842.4M | 824.9M |
| IPO Year | 1995 | 2013 |
| Metric | SCHL | TBPH |
|---|---|---|
| Price | $40.25 | $16.05 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $40.00 | $18.40 |
| AVG Volume (30 Days) | 262.4K | ★ 289.3K |
| Earning Date | 03-19-2026 | 05-04-2026 |
| Dividend Yield | ★ 1.99% | N/A |
| EPS Growth | N/A | ★ 279.13 |
| EPS | ★ 1.87 | N/A |
| Revenue | ★ $1,487,100,000.00 | $15,386,000.00 |
| Revenue This Year | $1.88 | $8.46 |
| Revenue Next Year | $4.05 | N/A |
| P/E Ratio | $21.91 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $16.81 | $9.98 |
| 52 Week High | $43.39 | $21.03 |
| Indicator | SCHL | TBPH |
|---|---|---|
| Relative Strength Index (RSI) | 52.51 | 40.51 |
| Support Level | $37.84 | $13.41 |
| Resistance Level | $43.39 | $17.21 |
| Average True Range (ATR) | 1.23 | 0.34 |
| MACD | 0.03 | -0.06 |
| Stochastic Oscillator | 68.36 | 4.84 |
Scholastic Corp is an American publishing and education media company that focuses on books and educational material for schools, teachers, parents, and children. It creates print, digital, and audiobooks, learning materials and programs, classroom magazines, and other products that support children's learning and reading both at home and at school. The company also owns rights to various books, including Harry Potter, Dog Man, and The Hunger Games among others. It has three reportable segments Children's Book Publishing and Distribution, Education Solutions, and International. The majority of its revenue is from the Children's Book Publishing and Distribution segment.
Theravance Biopharma Inc is a biopharmaceutical company focused on the development and commercialization of medicines to improve patients lives. The company leverages decades of expertise and has developed FDA-approved YUPELRI (revefenacin) inhalation solution for the maintenance treatment of patients with COPD. Its ampreloxetine Phase 3 clinical study (CYPRESS) for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy did not meet its primary endpoint. The company operates in a single segment, the development and commercialization of human therapeutics, and operates in the United States, which generates maximum revenue, and Europe.